|By PR Newswire||
|March 21, 2014 01:00 PM EDT||
VANCOUVER, March 21, 2014 /PRNewswire/ - Angiotech Pharmaceuticals, Inc. ("ANPI") today announced its financial results for the quarter and year ended December 31, 2013 as well as number of recent developments.
"We are pleased to have concluded 2013 by recording yet another year of improved business results as compared to the past several years," said Tammy Neske, Chief Business Officer of Angiotech. "2013 was a year of exceptional achievement, beginning with the successful sale of our interventional products business and a significant return of capital to our shareholders, followed by a new financing and an additional return of capital to our shareholders, the development of a new sales distribution and product development strategy, and the re-branding of our operating company to Surgical Specialties Corporation."
Amendment of Senior Secured Credit Facility: To enhance our operational flexibility and to support future growth, on March 18 2014, we completed an amendment to the Senior Secured Credit Facility of our subsidiary, Surgical Specialties Corporation (US), Inc. ("SSC"). The amendment provides for, among other things: (i) an increase in our incremental borrowing capacity from $25 million to $60 million; (ii) an increase in the amount of restricted payments that SSC can make to its parent company, Angiotech; (iii) a reduction from 50% to 25% in the amount of excess cash flow that must be used to repay debt; and (iv) an increase in call protection from 101 for 12 months to 102 for 6 months and 101 for 6 months.
New Member of the Board of Directors: Earlier this year, Richard Packer joined our Board of Directors. Mr. Packer is currently the CEO at Zoll Medical Corporation, a leader in medical products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management. Mr. Packer joined Zoll in 1992 as the Vice President of Operations and has since held a number of senior executive positions at Zoll. Prior to 1992, he was Vice President of various functions at Whistler Corporation, a consumer electronics company.
Certainty on Cook Royalty Obligation on Sales of the Zilver PTX Drug Eluting Peripheral Stent: On December 12, 2013 we entered into an agreement with Cook Incorporated, licensor of certain patents that brings certainty to the term of Cook's royalty obligation to Angiotech irrespective of patent life. The agreement obligates Cook to pay 10% on US sales through the end of 2017, 4.5% on US sales 2018 through 2020, and 8% on EU sales through the end of 2017.
Expansion of Product Portfolio: Through the fall of 2013 we completed significant needle development and suture line extension projects, resulting in the launch of new SSC Surgical Suture and SSC Animal Health Suture products, a Quill Animal Health product line, additional new Quill product codes for human use (making our barbed wound closure device portfolio the most robust barbed device portfolio on the market), and new "300 series" needles (demonstrating improved strength, flexibility and tissue penetration characteristics) for sale to our OEM customers. Testing conducted to date indicates that the new SSC needles perform comparable to or better than, competitive needle offerings.
Transfer of US Manufacturing to Low Cost Environment: In February 2014, we announced our decision to transition manufacturing from our Reading, PA and Aguadilla, PR manufacturing plants to a new manufacturing facility in Tijuana, Mexico. The closure of these facilities is estimated to be complete by the end of 2015. The move to Tijuana is expected to allow us to operate more efficiently and cost effectively in one consolidated manufacturing site, position the company more competitively in the markets it serves, and improve our opportunities to grow and expand.
Product revenue for the year ended December 31, 2013 was $128.8 million,
an increase of 5% from $123.1 million recorded in 2012. The
year-over-year improvement in sales was primarily driven by strong
demand for our core suture lines and our microsurgical knives in the US
and Asia and continued growth in the overall sales of our various
knotless suture product lines.
Product revenue for Q4 2013 was $30.2 million, down 6% from $32.1
million in Q4 2012. Quarter-over-quarter results were impacted
primarily by buying patterns of certain of our OEM and private label
customers, including Ethicon, our sole private label customer for our
knotless suture product lines, and competitive pressure in the U.S. for
direct sales of Quill.
While our direct sales of Quill in the U.S. declined during the year,
coincident with Ethicon's product launch, they have subsequently
stabilized and have begun to again show growth. In addition, our Quill
sales in Asia continue to grow and almost doubled year-over-year.
Importantly, even with the lower average selling price we receive on our
private label sales of knotless suture products to our partner Ethicon,
when combined with our own direct sales of Quill, our total revenues
from knotless suture technology continued to exhibit growth consistent
with previous years, up 9% in 2013 as compared to 2012.
In addition, our sales force reorganization activities began to yield
benefits for our overall wound closure product lines in 2013.
Specifically, our 2013 sales of our non-Quill suture product lines for
both Q4 and the full year grew 6% as compared to the same periods of
2012. In the hands of our direct sales team, micro suture product
revenues grew 13% quarter-over-quarter and 10% year-over-year.
Royalty revenue for 2013 was $5.5 million, down 64% from $15.1 million
recorded in 2012. Royalty revenue for Q4 2013 was $1.6 million, down
47% from $3.0 million in Q4 2012. The vast majority of the decline was
due to lower royalties revenues on sales by Boston Scientific
Corporation of TAXUS® drug-eluting stents. Compared to 2013, royalties
were also down in both Q4 and the year in 2013 compared to last year
due to a reversal of royalties earned in prior periods from Cook
associated with their voluntary recall of Zilver PTX drug-eluting
stents in April 2013. Since the recall, royalty revenues from Cook in
the most recent quarter were up 17%.
Adjusted EBITDA for the year ended December 31, 2013 was $36.7 million,
a reduction of 19% from $45.1 million (pro forma for the sale of our
interventional products business) recorded in 2012, consisting of an
increase of $2.3 million from Adjusted EBITDA of $31.4 million for SSC
in 2012, offset by a decline of $10.7 million from Adjusted EBITDA of
$13.7 million for our Royalty business in 2012.
Adjusted EBITDA for Q4 2013 was $6.9 million, down 41% from $11.7
million in Q4 2012. Compared to the same quarter last year, Q4 2013
Adjusted EBITDA for SSC of $7.3 million declined by $1.0 million and Q4
2013 Adjusted EBITDA for our Royalty business of ($0.4) million
declined by $3.8 million.
Lower royalty revenues negatively impacted Adjusted EBITDA for both the
full year and Q4 of 2013, and for the year more than offset the strong
performance of our SSC business. The lower margins we receive on
private label sales of knotless suture products to Ethicon also
impacted SSC's 2013 annual and Q4 Adjusted EBITDA.
- As of December 31, 2013, ANPI held $17.3 million of unrestricted cash & cash equivalents, of which $13.4 million was held by SSC, and $107.3 million of its floating rate notes were outstanding.
Certain financial measures in this press release are prepared in accordance with U.S. Generally Accepted Accounting Principles ("GAAP"). In addition, we have presented adjusted earnings before interest, taxes, depreciation and amortization ("Adjusted EBITDA"), which is a non-GAAP financial metric that excludes certain non-cash and non-recurring items. Management uses Adjusted EBITDA to establish operational goals, and believes that this metric may assist investors in evaluating the results of our business and analyzing the underlying trends over time. In addition, our creditors may monitor this metric to measure compliance with certain financial covenants in our lending agreements, or assess the operating and cash flow performance of our business. Investors should consider our non-GAAP Adjusted EBITDA in addition to, and not as a substitute for, or as superior to, financial metrics prepared in accordance with GAAP.
Amounts, unless specified otherwise, are expressed in U.S. dollars. Financial results are reported in accordance with U.S. GAAP unless otherwise noted.
Forward Looking Statements
Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimates," "continues," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities in 2014 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research and development and product development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions in the United States, Canada and the other regions in which we operate; market demand; competition; technological changes that could impact our existing products or our ability to develop and commercialize future products; governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; availability of financial reimbursement coverage from governmental and third-party payers for products and related treatments; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for funding to conduct research and development, to expand manufacturing and commercialization activities; and any other factors that may affect our performance. In addition, our business is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to successfully manufacture, market and sell our products; changes in our business strategy or development plans; our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third-party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; the availability of capital to finance our activities; our ability to service our debt obligations; and any other factors referenced in our other filings with the SEC.
Given these uncertainties, assumptions and risk factors, investors are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.
©2013 Angiotech Pharmaceuticals, Inc. All Rights Reserved.
Angiotech is a medical device business operating in the United States, the United Kingdom and Puerto Rico that develops, manufactures and markets medical device products and technologies, primarily in the areas of suture, surgical needle technologies and micro-surgical blades, through its subsidiary, Surgical Specialties Corporation (US), Inc. Key product lines include wound closure products such as the Quill™ knotless tissue closure device, Surgical Specialties Surgical Suture, and Look™ brand sutures, Sharpoint and Surgical Specialties Microsurgical Knives brand of microsurgical knives. Angiotech also manufactures components and private label suture and microsurgical knives for other third party medical device manufacturers. For additional information about Angiotech, please visit our website at www.surgicalspecialties.com.
SOURCE Angiotech Pharmaceuticals, Inc.
In the next forty months – just over three years – businesses will undergo extraordinary changes. The exponential growth of digitization and machine learning will see a step function change in how businesses create value, satisfy customers, and outperform their competition. In the next forty months companies will take the actions that will see them get to the next level of the game called Capitalism. Or they won’t – game over. The winners of today and tomorrow think differently, follow different...
Oct. 22, 2016 04:30 AM EDT Reads: 793
One of biggest questions about Big Data is “How do we harness all that information for business use quickly and effectively?” Geographic Information Systems (GIS) or spatial technology is about more than making maps, but adding critical context and meaning to data of all types, coming from all different channels – even sensors. In his session at @ThingsExpo, William (Bill) Meehan, director of utility solutions for Esri, will take a closer look at the current state of spatial technology and ar...
Oct. 22, 2016 03:30 AM EDT Reads: 1,661
The Open Connectivity Foundation (OCF), sponsor of the IoTivity open source project, and AllSeen Alliance, which provides the AllJoyn® open source IoT framework, today announced that the two organizations’ boards have approved a merger under the OCF name and bylaws. This merger will advance interoperability between connected devices from both groups, enabling the full operating potential of IoT and representing a significant step towards a connected ecosystem.
Oct. 22, 2016 02:45 AM EDT Reads: 1,148
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his session at @DevOpsSummit 19th Cloud Expo, Eric Robertson, General Manager at CollabNet, will show how customers are able to achieve a level of transparency that enables everyon...
Oct. 22, 2016 02:45 AM EDT Reads: 1,242
SYS-CON Events announced today that Interface Masters Technologies, a leader in Network Visibility and Uptime Solutions, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Interface Masters Technologies is a leading vendor in the network monitoring and high speed networking markets. Based in the heart of Silicon Valley, Interface Masters' expertise lies in Gigabit, 10 Gigabit and 40 Gigabit Eth...
Oct. 22, 2016 02:45 AM EDT Reads: 3,284
As software becomes more and more complex, we, as software developers, have been splitting up our code into smaller and smaller components. This is also true for the environment in which we run our code: going from bare metal, to VMs to the modern-day Cloud Native world of containers, schedulers and microservices. While we have figured out how to run containerized applications in the cloud using schedulers, we've yet to come up with a good solution to bridge the gap between getting your conta...
Oct. 22, 2016 02:00 AM EDT Reads: 1,390
DevOps theory promotes a culture of continuous improvement built on collaboration, empowerment, systems thinking, and feedback loops. But how do you collaborate effectively across the traditional silos? How can you make decisions without system-wide visibility? How can you see the whole system when it is spread across teams and locations? How do you close feedback loops across teams and activities delivering complex multi-tier, cloud, container, serverless, and/or API-based services?
Oct. 22, 2016 01:45 AM EDT Reads: 942
SYS-CON Media announced today that @WebRTCSummit Blog, the largest WebRTC resource in the world, has been launched. @WebRTCSummit Blog offers top articles, news stories, and blog posts from the world's well-known experts and guarantees better exposure for its authors than any other publication. @WebRTCSummit Blog can be bookmarked ▸ Here @WebRTCSummit conference site can be bookmarked ▸ Here
Oct. 22, 2016 01:30 AM EDT Reads: 9,608
SYS-CON Events announced today that Streamlyzer will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Streamlyzer is a powerful analytics for video streaming service that enables video streaming providers to monitor and analyze QoE (Quality-of-Experience) from end-user devices in real time.
Oct. 22, 2016 01:15 AM EDT Reads: 889
You have great SaaS business app ideas. You want to turn your idea quickly into a functional and engaging proof of concept. You need to be able to modify it to meet customers' needs, and you need to deliver a complete and secure SaaS application. How could you achieve all the above and yet avoid unforeseen IT requirements that add unnecessary cost and complexity? You also want your app to be responsive in any device at any time. In his session at 19th Cloud Expo, Mark Allen, General Manager of...
Oct. 22, 2016 01:15 AM EDT Reads: 807
@ThingsExpo has been named the Top 5 Most Influential Internet of Things Brand by Onalytica in the ‘The Internet of Things Landscape 2015: Top 100 Individuals and Brands.' Onalytica analyzed Twitter conversations around the #IoT debate to uncover the most influential brands and individuals driving the conversation. Onalytica captured data from 56,224 users. The PageRank based methodology they use to extract influencers on a particular topic (tweets mentioning #InternetofThings or #IoT in this ...
Oct. 22, 2016 01:00 AM EDT Reads: 8,149
Today every business relies on software to drive the innovation necessary for a competitive edge in the Application Economy. This is why collaboration between development and operations, or DevOps, has become IT’s number one priority. Whether you are in Dev or Ops, understanding how to implement a DevOps strategy can deliver faster development cycles, improved software quality, reduced deployment times and overall better experiences for your customers.
Oct. 22, 2016 12:30 AM EDT Reads: 516
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in Embedded and IoT solutions, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 7-9, 2017, at the Javits Center in New York City, NY. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology, is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/Big Data, HPC and ...
Oct. 22, 2016 12:30 AM EDT Reads: 3,490
Cloud based infrastructure deployment is becoming more and more appealing to customers, from Fortune 500 companies to SMEs due to its pay-as-you-go model. Enterprise storage vendors are able to reach out to these customers by integrating in cloud based deployments; this needs adaptability and interoperability of the products confirming to cloud standards such as OpenStack, CloudStack, or Azure. As compared to off the shelf commodity storage, enterprise storages by its reliability, high-availabil...
Oct. 22, 2016 12:15 AM EDT Reads: 967
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an Internet of Things implementation? In his session at @ThingsExpo, James Kirkland, Red Hat's Chief Arch...
Oct. 22, 2016 12:00 AM EDT Reads: 5,935